DBV Technologies dépose un prospectus relatif à son Programme At-The-Market (ATM) pour un montant pouvant atteindre 150 millions de dollars

DBV Technologies has filed a new S-3ASR registration statement with the SEC to renew its at-the-market (ATM) offering program for up to $150 million in American Depositary Shares (ADSs). The company plans to use proceeds primarily for manufacturing capacity expansion, pediatric BLA submissions for peanut allergy treatment, and product development. The program was established with Citizens JMP Securities as the placement agent.